394 related articles for article (PubMed ID: 11207278)
21. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis.
Hollenbaugh JA; Reome J; Dobrzanski M; Dutton RW
J Immunol; 2004 Aug; 173(3):1738-43. PubMed ID: 15265903
[TBL] [Abstract][Full Text] [Related]
22. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity.
Medana I; Li Z; Flügel A; Tschopp J; Wekerle H; Neumann H
J Immunol; 2001 Jul; 167(2):674-81. PubMed ID: 11441070
[TBL] [Abstract][Full Text] [Related]
23. Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor.
Shimizu M; Yoshimoto T; Sato M; Morimoto J; Matsuzawa A; Takeda Y
Int J Cancer; 2005 May; 114(6):926-35. PubMed ID: 15645421
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a T cell clone and of T cells from a TCR transgenic mouse: TCR transgenic T cells specific for self-antigen are atypical.
Dobbs C; Haskins K
J Immunol; 2001 Feb; 166(4):2495-504. PubMed ID: 11160310
[TBL] [Abstract][Full Text] [Related]
25. Double-negative T cells, activated by xenoantigen, lyse autologous B and T cells using a perforin/granzyme-dependent, Fas-Fas ligand-independent pathway.
Zhang ZX; Ma Y; Wang H; Arp J; Jiang J; Huang X; He KM; Garcia B; Madrenas J; Zhong R
J Immunol; 2006 Nov; 177(10):6920-9. PubMed ID: 17082607
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis.
Simon MM; Waring P; Lobigs M; Nil A; Tran T; Hla RT; Chin S; Müllbacher A
J Immunol; 2000 Oct; 165(7):3663-72. PubMed ID: 11034370
[TBL] [Abstract][Full Text] [Related]
27. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
[TBL] [Abstract][Full Text] [Related]
28. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms.
Kafrouni MI; Brown GR; Thiele DL
J Immunol; 2001 Aug; 167(3):1566-74. PubMed ID: 11466378
[TBL] [Abstract][Full Text] [Related]
29. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand.
Ng CS; Lo ST; Chan JK
Hum Pathol; 1999 Jan; 30(1):48-53. PubMed ID: 9923926
[TBL] [Abstract][Full Text] [Related]
30. A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation.
Li-Weber M; Laur O; Hekele A; Coy J; Walczak H; Krammer PH
Eur J Immunol; 1998 Aug; 28(8):2373-83. PubMed ID: 9710215
[TBL] [Abstract][Full Text] [Related]
31. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice.
Li Q; Nakadai A; Takeda K; Kawada T
Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847
[TBL] [Abstract][Full Text] [Related]
32. Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection.
Walsh CM; Hayashi F; Saffran DC; Ju ST; Berke G; Clark WR
J Immunol; 1996 Feb; 156(4):1436-41. PubMed ID: 8568245
[TBL] [Abstract][Full Text] [Related]
33. CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo.
Nishimatsu H; Takeuchi T; Ueki T; Kajiwara T; Moriyama N; Ishida T; Li B; Kakizoe T; Kitamura T
Cancer Immunol Immunother; 1999 Apr; 48(1):56-61. PubMed ID: 10235489
[TBL] [Abstract][Full Text] [Related]
34. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
35. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.
Hayakawa Y; Kelly JM; Westwood JA; Darcy PK; Diefenbach A; Raulet D; Smyth MJ
J Immunol; 2002 Nov; 169(10):5377-81. PubMed ID: 12421908
[TBL] [Abstract][Full Text] [Related]
36. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
37. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
[TBL] [Abstract][Full Text] [Related]
38. Differential regulation of the expression of CD95 ligand, receptor activator of nuclear factor-kappa B ligand (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), and TNF-alpha during T cell activation.
Wang R; Zhang L; Zhang X; Moreno J; Luo X; Tondravi M; Shi Y
J Immunol; 2001 Feb; 166(3):1983-90. PubMed ID: 11160247
[TBL] [Abstract][Full Text] [Related]
39. TNF receptor 2-deficient CD8 T cells are resistant to Fas/Fas ligand-induced cell death.
Teh HS; Seebaran A; Teh SJ
J Immunol; 2000 Nov; 165(9):4814-21. PubMed ID: 11046004
[TBL] [Abstract][Full Text] [Related]
40. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
